Enzymatic resolution of cyclic N-Boc protected β-aminoacids
摘要:
Methyl and ethyl esters of N-Boc homoproline, homopipecolic acid and 3-carboxymethyl-morpholine were kinetically resolved by hydrolysis catalysed by Burkholderia cepacia lipase to give the corresponding acids and residual esters in enantiomeric excesses better than 99% (E > 100). (C) 2004 Published by Elsevier Ltd.
BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
申请人:Gilead Sciences, Inc.
公开号:US20160333009A1
公开(公告)日:2016-11-17
The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I:
or pharmaceutically acceptable salts thereof, in which X, L, n, m, R
1
, R
2a
, R
2b
, R
n
, R
m
, and R
t
are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.
本公开提供了式I的吲哌酮2,3-二氧化酶1(IDOL)抑制剂:
或其药学上可接受的盐,其中X、L、n、m、R
1
、R
2a
、R
2b
、R
n
、R
m
和R
t
如本文所定义,以及包括式I化合物的药物组合物,或其药学上可接受的盐,并使用这些方法来治疗由IDO1介导的疾病。
CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
申请人:FLX Bio, Inc.
公开号:US20180072743A1
公开(公告)日:2018-03-15
Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.
披露的内容包括但不限于,用于调节趋化因子受体活性的化合物及其使用方法。
Energetic contribution to both acidity and conformational stability in peptide models
The acidity difference of the amide rotamers has been revised for a large set ofN-acetyl amino acids.
酰胺构象异构体的酸度差异已经针对大量的N-乙酰氨基酸进行了修订。
[EN] COMPOUNDS ACTIVE TOWARDS BROMODOMAINS<br/>[FR] COMPOSÉS ACTIFS ENVERS DES BROMODOMAINES
申请人:NUEVOLUTION AS
公开号:WO2016016316A1
公开(公告)日:2016-02-04
Disclosed are compounds towards bromodomains, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
揭示了针对溴结构域的化合物,含有这些化合物的药物组合物以及这些化合物在治疗中的用途。
Methylphenidate-Prodrugs, Processes of Making and Using the Same
申请人:KemPharm, Inc.
公开号:US20150266911A1
公开(公告)日:2015-09-24
The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.